Taiwan NHI excludes coverage for new Alzheimer's drug Kisunla

Kisunla, a newly approved Alzheimer's drug in Taiwan, will not be covered by the National Health Insurance (NHI) system, while coverage for Leqembi, another Alzheimer's treatment approved this year, is still under review, a health official overseeing the NHI system said Thursday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)